


## 1. Rare Honour – Asian Age



## 2. Lay thrust on research : Gov to pharma – Asian Age



## 3. Photo Caption - Navbharat



## 4. [Health's vanished from Modi govt focus: Lancet](#) – ET Health World

Lancet, the widely-respected medical journal, has criticised the Modi government for not paying sufficient attention to India's health sector and has warned that the country could face a serious crisis under the weight of its own ill health.

## 1. Rare Honour – Asian Age

## 2. Lay thrust on research : Gov to pharma – Asian Age

## 3. Photo Caption – Navbharat

## 4. [Health's vanished from Modi govt focus: Lancet](#) – ET Health World

## 5. [Mandatory code for pharma marketing on the anvil](#) – Times of India

## 6. [ICMR drafts rules on child drug trial](#) – ET Health world

## 7. [Canada's new PM urged to fast-track free trade agreement with India](#) – Business Standard

## 8. [India and Russia target \\$30 billion worth trade in next 10 years](#) – Economic Times

## 9. [Bitter Pill | E-Pharmacies: Don't Open Yet Another Big Avenue For Counterfeiters Now](#) – Business World

## 10. [Biocon targets emerging, developed markets with biosimilars](#) – Economic Times

## 11. [Sun Pharma settles patent litigation with Acorda Therapeutics](#) – Economic Times

## 12. [Strides Acquires 7 J&J Brands, Majority Stake in Medispan](#) – Economic Times

The journal will take the Indian government to task for failing to make health a priority, while drawing attention to Modi's poll promise of rolling out universal health coverage in a paper-written by some of the top medical experts-in its edition of December 11.

5. [\*\*Mandatory code for pharma marketing on the anvil\*\*](#) – Times of India

Pharma companies may have to cough up huge penalties for unethical and illegal practices like offering freebies, gifts and foreign trips to doctors for pushing the sales of their products.

The government is set to make mandatory the uniform code of conduct for pharmaceutical marketing practices, which have so far been voluntary. The department of pharmaceuticals (DoP) is working on a draft which will curb unethical marketing methods and ban specific practices such as giving gifts and sponsor vacations of doctors by drug manufacturers, an official source said.

6. [\*\*ICMR drafts rules on child drug trial\*\*](#) – ET Health world

Researchers may have to comply with stringent ethical and legal norms for testing new medicines on children. The Indian Council of Medical Research (ICMR) has issued draft guidelines for biomedical research on children, a move aimed at ensuring safe trials on children who are sensitive to side effects and adverse reactions.

The draft guidelines state that drugs should be tested for safety, pharmacokinetics, and at least initial indications of efficacy in adults before being tested on children. It may often be appropriate to defer paediatric testing until adult testing has reached phase 3 or beyond, when substantial data is available on the safety and efficacy of a drug in adults.

7. [\*\*Canada's new PM urged to fast-track free trade agreement with India\*\*](#) – Business Standard

Welcoming the incoming Canadian prime minister Justin Trudeau whose Liberal Party was swept to power yesterday, major Indo-Canadian organizations have urged him to fast-track the long-pending free trade agreement with India.

Ajit Someshawar, chairman of the Canada-India Foundation (CIF), urged Trudeau to make a state visit to India as one of his foreign policy priorities and conclude the long-pending Comprehensive Economic Partnership Agreement (CEPA) and the Foreign Investment Protection Agreement (FIPA) between the Canada and India.

8. [\*\*India and Russia target \\$30 billion worth trade in next 10 years\*\*](#) – Economic Times

India and Russia have discussed ways to boost their economic ties to achieve the target of \$30 billion in bilateral trade in the next 10 years.

External Affairs Minister Sushma Swaraj and Russia's Deputy Prime Minister Dmitry Rogozin, chairing the 21st India-Russia Inter-Governmental Consultations yesterday, also looked at ways to enhance the mutual direct investment to \$15 billion by 2025.

9. [\*\*Bitter Pill | E-Pharmacies: Don't Open Yet Another Big Avenue For Counterfeiters Now\*\*](#) – Business World

Online pharmacies have been the talk of the town in the last fortnight after the country's 9,00,000 odd chemists closed shops on October 14 to protest the government move to appoint a committee for making a regulatory framework for e-pharmacies. E-pharmacies are not very new to Indian patients as scores of them pop up on your browser every time you open one. Most of these online pharmacies which offer nutritional products to sex enhancing capsules, including several prescription drugs, do not show their addresses or the source of the products that they offer to deliver.

These online stores also offer heavy discounts on branded medicines and other pharmaceutical products as compared to the original prices. But, because these websites have their servers

based outside the country, Indian regulators did not have any clue on their whereabouts and how to monitor them. So it remained alive since long. There is no official statistics available to show how many people lost their money or how many patients got cured from their diseases with the orders delivered through these websites so far, in India.

10. [Biocon targets emerging, developed markets with biosimilars](#) – Economic Times

Biopharmaceuticals firm Biocon is looking to tap opportunities in biosimilars targeting diseases such as diabetes and cancer among others, in both emerging and developed markets. The company expects regulatory filings in the US and Europe by 2016-17 for some of its biosimilars out of the five development programmes that it is currently undertaking with pharma firm Mylan.

Biosimilars are types of biological products that are used for treatment of various diseases.

11. [Sun Pharma settles patent litigation with Acorda Therapeutics](#) – Economic Times

Sun Pharma BSE -1.43 % has settled a patent litigation with US-based Acorda Therapeutics Inc over Ampyra extended-release tablets, which is used in the treatment of multiple sclerosis patients.

As per the settlement the Indian drug major can launch its generic version of the medicine in the US by 2027.

12. [Strides Acquires 7 J&J Brands, Majority Stake in Medispan](#) – Economic Times

Strides Arcolab, an Indian drug manufacturer, has expanded its portfolio of offerings by acquiring brands from two companies in separate transactions.

Strides signed a deal with Johnson & Johnson to buy seven of its brands in the dermatology, antiemetic and pain management segments. The portfolio acquired from J&J includes Otogesic eardrops, Ehnorub ointment and Stugil tablets, Strides said in a statement to the stock exchange on Wednesday.